



Therapy Training

Supporting the growth and development of MDMA-assisted psychotherapy practitioners and sites

The MDMA Therapy Training Program offers in-depth training into the practice of MDMA-Assisted Psychotherapy, with curriculum based on decades of clinical experience. Trainees learn the theoretical approach of the modality, developed from the fundamental notion that every person has within them an incredible source of wisdom and an innate ability to heal.

The MDMA Therapy Training Program provides the training and supervision required to qualify practitioners to deliver MDMA-Assisted Psychotherapy in approved clinical settings. As of Summer 2020, the MDMA Therapy Training Program has enrolled over 700 clinicians and delivered trainings in the United States, United Kingdom, Canada, the Netherlands, and Israel.

The MDMA Therapy Training Program enrolls compassionate and experienced clinicians who are committed to health and well-being. The program is currently accepting applications for mental health practitioners interested in learning the modality of MDMA-Assisted Psychotherapy.



MDMA-Assisted Psychotherapy Treatment Manual

Want to learn more about MDMA-Assisted Psychotherapy?

Download

Therapy Training Updates

To receive updates as training opportunities become available, please provide your name and email address.

First Name

Last Name

Email

Subscribe

MDMA-assisted psychotherapy is currently provided by trained mental health and medical practitioners working on approved clinical research protocols at facilities that meet government regulatory requirements for drug storage. At this time research protocols are limited. As Phase 3 trials continue, data is being collected to support a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in 2021, with the hopes of making MDMA-Assisted Psychotherapy into an approved prescription treatment. The MDMA Therapy Training Program is a pre-requisite for conducting MDMA-Assisted Psychotherapy on a MAPS protocol and is expected to continue as required training for clinicians offering MDMA-Assisted Psychotherapy post-approval, through the Risk Evaluation and Mitigation Strategy (REMS). The MDMA Therapy Training Program delivers specialized training to build competency for the conduct of this modality and ensure that practitioners are offering the treatment in a safe, effective, and ethical manner.

On December 20, 2019, the U.S. Food and Drug Administration (FDA) agreed to MAPS' application for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). The program's purpose is to grant access to potentially beneficial investigational treatments for people facing a serious or immediately life-threatening condition for which there is no satisfactory treatment currently available.

The following are the current required elements for providing MDMA-Assisted Psychotherapy in an approved protocol:

1. Protocol: availability of an approved study protocol with capacity for additional sites.
2. Site: a treatment facility conducive to MDMA-assisted psychotherapy, as confirmed by the sponsored study team and in compliance with standard procedure.
3. Physician: a prescribing physician who can obtain a Drug Enforcement Administration (DEA) Schedule I license (or equivalent for countries outside the US) for MDMA. A second, back-up physician may be necessary to accommodate the requirement to have a physician available on-call.
4. Therapy Team: two or more qualified therapists affiliated with the approved site, who have successfully completed the MDMA Therapy Training Program and been recommended to become providers in an approved protocol.

More information on these requirements is outlined on the Application Requirements page. Before submitting your application, make sure to read through all of the requirements.

[Application Requirements](#)



The 5-part training program is required for all MDMA-assisted therapy practitioners working on a MAPS protocol.





PART A

ONLINE COURSE

The online course outlines chemistry and history of MDMA, common reactions, possible mechanisms of action, and study design. The online course was developed out of content from the Treatment Manual, study protocols, and scientific literature on the subject.

MDMA Therapy Training Program Connect Portal

The MDMA Therapy Training Program Connect Portal is a community discussion forum for therapy providers, physicians and sites to connect with one another to network and meet the qualifications to become eligible to work on an MDMA-assisted psychotherapy protocol. If you are looking for treatment staff, a physician, or a treatment facility, we hope that this platform will support you. In addition to community discussion, staff members of the MDMA Therapy Training Program provide some moderation of the discussion forums.

[Connect Portal](#)

Tuition and Scholarships

Tuition rates and training dates will be announced when enrollment occurs.

If you would like to support MDMA Therapy Training opportunities for people of color, please consider donating [to this effort](#). Your donation is tax deductible and will help to build equity and inclusion for this important new healing modality.

Additional scholarship programs are under development.



Apply

MAPS PBC is currently conducting MDMA-assisted psychotherapy trials in the United States, Canada, Israel, the United Kingdom, and the European Union. While we are not actively recruiting new sites or therapists at this time, we are still accepting online applications for sites and providers who would like to be considered when opportunities open up in the future. The MDMA Therapy Training Program expects to open enrollment for the 2021 training year in the months ahead, at which point candidates who have an application on file will be reviewed and screened for enrollment. If you are interested in participating in the training program, please review the materials on this website, including the Application Requirements. Applicants who are affiliated with a site and a qualified therapy team will be prioritized so that we can better translate training resources into the most participants receiving treatment. Please sign up for emails on this page to receive updates on training opportunities for the MDMA Therapy Training Program.

[Site Questionnaire](#)

The MDMA Therapy Training Program is currently accepting Practitioner Training Applications from qualified applicants who would like to begin their training in the MDMA Therapy Training Program. Applications are reviewed on an ongoing basis, as they are received; applicants will be notified of their application status and will be contacted if needed for clarification on their application responses. The MDMA Therapy Training Program is a prerequisite to working on a MAPS MDMA-Assisted Psychotherapy protocol; qualified practitioners who are enrolled in or have graduated from the MDMA Therapy Training Program will be considered for participation in future protocols, pending approval.

Due to the unpredictable nature of clinical research, we understand that many qualified practitioners may wish to wait until regulatory approval is granted, and opportunities to deliver MDMA-Assisted Psychotherapy are confirmed, before investing in their training with the MDMA Therapy Training Program. Please stay tuned to the [Connect Portal](#) and [MDMA Therapy Training Program Email Newsletter](#) where we will share updates on protocol status, training announcements, and other news related to MDMA-assisted psychotherapy. Thank you for your interest in healing, growth, and learning!

[Apply Now](#)

Code of Ethics

The MAPS MDMA Therapy Training Program is committed to providing quality and comprehensive training and supervision to support therapy providers in delivering ethical care within a MAPS MDMA-assisted psychotherapy protocol. As an organization, we take seriously our obligation to participant safety and to reflecting internally to promote ethical growth in our programs. In service to this commitment, the MDMA Therapy Training Program has established the MAPS MDMA-Assisted Psychotherapy Code of Ethics [\[Version 3: 19 October 2020\]](#). The Code will remain a living document to grow and adapt with the ongoing integration of feedback and evolution of needs over time.

In the process of researching and drafting the Code of Ethics, the MDMA Therapy Training Program has been grateful to draw on collective wisdom within both psychotherapeutic and psychedelic fields. We wish to acknowledge input offered by our reviewers, as well as the work of many organizations and individuals to develop existing ethical guidelines.

Reviewers:

Cedar Barstow, M.Ed., C.H.T.
Marca Cassidy, BSN, LMFT
Karen M. Cooper, M.A., RN
Leia Friedman, M.S.
Ismail Lourido Ali, JD
Annie Mithoefer, BSN
Michael Mithoefer, M.D.
Angella Okawa, LMFT
Marcela Ot'alara, LPC
Bruce Poulter, RN
Dominic A. Sisti, Ph.D.
Kylea Taylor, M.S., LMFT
Verena Wieloch, LPCA, LCAS
and the generous contributions
of many others.


Editors:

Shannon Clare Carlin, M.A.
Sarah Scheld, M.A.

Please sign up to receive updates via the MDMA Therapy Training Email Newsletter.

[Code of Ethics Document](#)

Meet the Therapy Training Team



Michael Mithoefer, M.D.
Senior Medical
Director for Medical
Affairs, Training and
Supervision

[Read More](#)



Shannon C. Carlin, M.A., A.M.F.T.
Director and Head of
Training and
Supervision

[Read More](#)




Annie Mithoefer, B.S.N.
Sub-Investigator,
MDMA-Assisted
Psychotherapy for
PTSD

[Read More](#)



Marcela Ot'alara, M.F.A., M.A., L.P.C.
Principal Investigator
for MDMA-Assisted
Psychotherapy
Research

[Read More](#)



Bruce D. Poulter, M.P.H.
Sub
Investigator/Clinical
Supervisor for
MDMA-Assisted
Psychotherapy
Research

[Read More](#)



**Ido Stemion,
Ph.D.**

[Read More](#)



**Keren Tzarfaty,
Ph.D., M.F.T.**

[Read More](#)

Resources

[Frequently Asked Questions](#)

[Newsletter Archive](#)

MAPS Public Benefit Corporation

[Our Mission](#)
[Who We Are](#)
[Careers](#)
[News](#)
[FAQ](#)
[Contact Us](#)

1115 Mission Street
Santa Cruz, CA 95060-9989

Our Research

[MDMA for PTSD](#)
[Expanded Access Program](#)
[Study Information](#)
[MDMA Brochure](#)
[Participate in Trials](#)


Therapy Training

[Overview](#)
[Application](#)
[Connect Portal](#)

Sign Up for Therapy Training News

MAPS PBC is a wholly-owned subsidiary of the [Multidisciplinary Association for Psychedelic Studies \(MAPS\)](#).
MAPS is a 501(c)(3) non-profit research and educational organization.

[Privacy Statement](#) | [Sitemap](#)

 [Creative Commons](#) - MAPS PBC 2020